Dirk Pamperin
Directeur/Membre du Conseil chez SYNTHAVERSE S.A.
Profil
Dirk Pamperin is currently the Managing Director at APOGEPHA Arzneimittel GmbH since 2018.
He is also a Member-Supervisory Board at Synthaverse SA since 2020.
Previously, he worked as the Vice President-Research & Development at Synthon BV from 2005 to 2012.
Before that, he was a Project Manager at APOGEPHA Arzneimittel GmbH from 2002 to 2005.
Dr. Pamperin holds a doctorate degree from Universität Stuttgart and an undergraduate degree from Technische Universität Braunschweig.
Postes actifs de Dirk Pamperin
| Sociétés | Poste | Début |
|---|---|---|
| SYNTHAVERSE S.A. | Directeur/Membre du Conseil | 01/01/2020 |
APOGEPHA Arzneimittel GmbH
 APOGEPHA Arzneimittel GmbH Medical/Nursing ServicesHealth Services APOGEPHA Arzneimittel GmbH engages in the research, development, marketing, and sale of pharmaceuticals in Urology. It offers drugs for the treatment of overactive bladder and urinary incontinence for adults and children. The firm also provides preparations for the treatment of urinary stone diseases, urinary tract infections, benign prostate syndrome, and bladder cancer. The company was founded by C. Stephan in 1882 and is headquartered in Dresden, Germany. | Directeur Général | 01/01/2018 |
Anciens postes connus de Dirk Pamperin
| Sociétés | Poste | Fin |
|---|---|---|
Synthon BV
 Synthon BV Pharmaceuticals: MajorHealth Technology Synthon BV produces pharmaceutical products. Its activities include development, registration, production, marketing and distribution of pharmaceutical alternatives. The firm has operations in Europe, North America and Asia. The company was founded in 1991 by Jacques Lemmens and is headquartered in Nijmegen, the Netherlands. | Directeur Technique/Scientifique/R&D | 01/01/2012 |
APOGEPHA Arzneimittel GmbH
APOGEPHA Arzneimittel GmbH Medical/Nursing ServicesHealth Services APOGEPHA Arzneimittel GmbH engages in the research, development, marketing, and sale of pharmaceuticals in Urology. It offers drugs for the treatment of overactive bladder and urinary incontinence for adults and children. The firm also provides preparations for the treatment of urinary stone diseases, urinary tract infections, benign prostate syndrome, and bladder cancer. The company was founded by C. Stephan in 1882 and is headquartered in Dresden, Germany. | Corporate Officer/Principal | 01/01/2005 |
Formation de Dirk Pamperin
| Technische Universität Braunschweig | Undergraduate Degree |
| Universität Stuttgart | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNTHAVERSE S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
APOGEPHA Arzneimittel GmbH
APOGEPHA Arzneimittel GmbH Medical/Nursing ServicesHealth Services APOGEPHA Arzneimittel GmbH engages in the research, development, marketing, and sale of pharmaceuticals in Urology. It offers drugs for the treatment of overactive bladder and urinary incontinence for adults and children. The firm also provides preparations for the treatment of urinary stone diseases, urinary tract infections, benign prostate syndrome, and bladder cancer. The company was founded by C. Stephan in 1882 and is headquartered in Dresden, Germany. | Health Services |
Synthon BV
Synthon BV Pharmaceuticals: MajorHealth Technology Synthon BV produces pharmaceutical products. Its activities include development, registration, production, marketing and distribution of pharmaceutical alternatives. The firm has operations in Europe, North America and Asia. The company was founded in 1991 by Jacques Lemmens and is headquartered in Nijmegen, the Netherlands. | Health Technology |
